Q-Med AB invites to Year-End Report 2010 conference call

Q-Med's Year-End Report for the period January-December 2010 will be published
at 08.00 a.m. on Monday January 31, 2011, instead of, as earlier announced, on
February 11, 2011.

Media and analysts are invited to participate in a press conference at which the
report will be presented by Maria Carell, President and CEO and Alexander
Kotsinas, CFO.

Time: Monday January 31 at 10:30 a.m. CET.
Conference id: 88 64 11

To join the conference call dial: Sweden +46 8 505 201 14 or UK +44 (0)20
7162 0177.

The slide presentation will be available at www.q-med.com and
Investors/Presentations.

A recorded version of the presentation will be available for seven working days
on tel: Sweden +46 8 505 203 33 or UK +44 (0)20 7031 4064, access code 88 64 11.

Financial information 2011
January 31, Year-End Report January - December 2010
April 27, Interim Report January - March 2011
April 28, Annual General Meeting
July 21, Half Year Financial Report January - June 2011
October 26, Interim Report January - September 2011


Queries should be addressed to:
Camilla Schartau, IR Co-ordinator
Tel: +46 733 87 14 22


Q-Med AB is a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta® for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q-Med today has about 650 coworkers, with almost 400 at the company's
head office and production facility in Uppsala, Sweden. Q-Med AB is listed in
the Mid Cap segment of the NASDAQ OMX Nordic.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com. Web: www.q-
med.com.

[HUG#1482355]